These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 22289353)

  • 1. Immunocytokines: a novel class of potent armed antibodies.
    Pasche N; Neri D
    Drug Discov Today; 2012 Jun; 17(11-12):583-90. PubMed ID: 22289353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EDB-fibronectin antibody case.
    Ronca R; Sozzani S; Presta M; Alessi P
    Immunobiology; 2009; 214(9-10):800-10. PubMed ID: 19625102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
    Hess C; Neri D
    Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity.
    Neri D
    Cancer Immunol Res; 2019 Mar; 7(3):348-354. PubMed ID: 30824549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-cytokine fusion proteins.
    Kontermann RE
    Arch Biochem Biophys; 2012 Oct; 526(2):194-205. PubMed ID: 22445675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy.
    Hutmacher C; Neri D
    Adv Drug Deliv Rev; 2019 Feb; 141():67-91. PubMed ID: 30201522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
    Xiang J
    Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future prospects of monoclonal antibodies as magic bullets in immunotherapy.
    Maleki LA; Baradaran B; Majidi J; Mohammadian M; Shahneh FZ
    Hum Antibodies; 2013; 22(1-2):9-13. PubMed ID: 24284304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody fusions with immunomodulatory proteins for cancer therapy.
    Müller D
    Pharmacol Ther; 2015 Oct; 154():57-66. PubMed ID: 26145167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
    Pardridge WM; Boado RJ
    Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.
    Pasche N; Wulhfard S; Pretto F; Carugati E; Neri D
    Clin Cancer Res; 2012 Aug; 18(15):4092-103. PubMed ID: 22693354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.
    Frey K; Zivanovic A; Schwager K; Neri D
    Integr Biol (Camb); 2011 Apr; 3(4):468-78. PubMed ID: 21225052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and clinical development of immunocytokines.
    Sondel PM; Hank JA; Gan J; Neal Z; Albertini MR
    Curr Opin Investig Drugs; 2003 Jun; 4(6):696-700. PubMed ID: 12901228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.
    Murer P; Neri D
    N Biotechnol; 2019 Sep; 52():42-53. PubMed ID: 30991144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are targeted therapies really targeted?
    Schilsky RL
    Clin Adv Hematol Oncol; 2003 Dec; 1(12):722-3. PubMed ID: 16258475
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
    Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antibodies: better knowledge for a better use].
    Abès R; Dutertre CA; Teillaud JL
    Med Sci (Paris); 2009 Dec; 25(12):1011-9. PubMed ID: 20035672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
    Weber J
    Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
    Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
    J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.